SP
BravenNow
Lindt says weight-loss drugs users are eating more chocolate, not less
| USA | economy | ✓ Verified - investing.com

Lindt says weight-loss drugs users are eating more chocolate, not less

#Lindt #weight-loss drugs #chocolate consumption #consumer behavior #confectionery market #GLP-1 #demand #health trends

📌 Key Takeaways

  • Lindt reports increased chocolate consumption among users of weight-loss drugs
  • Contrary to expectations, these drugs are not reducing chocolate demand
  • The trend suggests potential shifts in consumer behavior linked to medication
  • Lindt's observation highlights an unexpected market dynamic in the confectionery industry

🏷️ Themes

Consumer Behavior, Health Trends

📚 Related People & Topics

Lindt

Lindt

Swiss chocolate maker founded in 1845

Chocoladefabriken Lindt & Sprüngli AG, doing business as Lindt, is a Swiss chocolatier and confectionery company founded in 1845 and known for its chocolate truffles and chocolate bars, among other sweets. It is based in Kilchberg, where its main factory and museum are located. Lindt is one of the l...

View Profile → Wikipedia ↗

Entity Intersection Graph

No entity connections available yet for this article.

Mentioned Entities

Lindt

Lindt

Swiss chocolate maker founded in 1845

Deep Analysis

Why It Matters

This news matters because it challenges the widespread assumption that weight-loss drugs automatically reduce consumption of indulgent foods like chocolate, revealing a more complex consumer behavior pattern. It affects chocolate manufacturers like Lindt who must adapt their marketing and product strategies to this new consumer segment. The findings also impact pharmaceutical companies developing weight-loss drugs and healthcare providers who counsel patients about dietary expectations. This insight could influence investment decisions in both the confectionery and pharmaceutical sectors.

Context & Background

  • Weight-loss drugs like Ozempic and Wegovy (GLP-1 agonists) have surged in popularity, creating a multi-billion dollar market that was projected to reduce demand for snack foods.
  • Major food companies including Nestlé and Hershey previously expressed concerns that these medications would negatively impact their sales of indulgent products.
  • Lindt & Sprüngli is a premium Swiss chocolate maker with global operations, known for higher-end products that might appeal differently to consumers on weight-management regimens.
  • The pharmaceutical industry has been promoting these drugs primarily for diabetes and obesity treatment, with dietary behavior changes being a key expected outcome.

What Happens Next

Food companies will likely conduct more targeted research into how weight-loss drug users actually modify their eating habits across different product categories. We may see chocolate manufacturers develop specific marketing campaigns or product lines tailored to this demographic. Pharmaceutical companies might incorporate these findings into their patient education materials about realistic dietary expectations while using these medications.

Frequently Asked Questions

Why would weight-loss drug users eat more chocolate?

Lindt suggests these consumers might be rewarding themselves with small indulgences while successfully managing their weight through medication, or they may be compensating for reduced consumption of other foods. The premium nature of Lindt's chocolate might make it a preferred 'treat' choice for those controlling their overall calorie intake.

How reliable is Lindt's assessment of this trend?

As a major chocolate manufacturer with access to sales data and consumer insights, Lindt's observations carry weight, though they should be verified through independent research. Their statement contrasts with earlier industry concerns, suggesting they've identified a specific pattern in their customer base.

What does this mean for other snack food companies?

Other companies may need to reevaluate their assumptions about how weight-loss drugs affect consumption patterns across different food categories. This could lead to more nuanced market segmentation and product development strategies rather than blanket predictions of reduced demand.

Could this change how doctors prescribe weight-loss drugs?

While unlikely to change prescription practices directly, it might influence dietary counseling by acknowledging that patients may still indulge in certain foods. Healthcare providers might discuss mindful indulgence strategies rather than assuming complete avoidance of treats like chocolate.

}
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Oil demand destruction would likely require prices around $155/bbl: Bernstein Futures rise as Trump says Iran war will end "very soon" - what’s moving markets Gold prices rise but still rangebound with focus on Iran war de-escalation Oil prices retreat as Trump hints at Iran war end, supply relief (South Africa Philippines Nigeria) Lindt says weight-loss drugs users are eating more chocolate, not less By Stock Markets Published 03/10/2026, 04:11 AM Updated 03/10/2026, 07:12 AM Lindt says weight-loss drugs users are eating more chocolate, not less 0 LLY 1.82% NVO 3.11% LISN -7.84% By John Revill and Danny Callaghan KILCHBERG, Switzerland March 10 - Chocolate sales are rising faster among U.S. users of GLP-1 weight-loss drugs than in the rest of the population, Swiss chocolatier Lindt & Spruengli said on Tuesday, citing data that defied forecasts the drugs would reduce confectionery demand. The company said an internal study, based on February data from market researcher Circana, found 15% of U.S. households use GLP-1s, representing 17.5% of chocolate sales. GLP-1s include weight-loss drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s (N:LLY) Mounjaro. Consumers cutting back on high-calorie intake categories, such as pasta, pizza and potato chips, are still looking for some kind of indulgence, chief executive Adalbert Lechner told a news conference on Tuesday. "They are upgrading to premium products. Less is more – small rewards with moment of bliss rather than mindless munching," said Lechner. Lindt, which makes chocolate Easter bunnies, said U.S. sales of premium chocolate increased among GLP-1 users by nearly 17% in 2025, compared to a 6.5% rise among non-GLP-1 users. Analysts at Berenberg had expected the introduction of oral GLP-1 weight-loss drugs to have an adverse effect on the food industry, particularly confectionery, over the next few years. They anticipated a drag on sales volumes of 0.9 percentag...
Read full article at source

Source

investing.com

More from USA

News from Other Countries

🇬🇧 United Kingdom

🇺🇦 Ukraine